✨ Onyx Summary Ocugen announced that CEO and co-founder Dr. Shankar Musunuri will present at NobleCon21 on December 3, 2025, where he plans to outline progress toward the company’s goal of “three BLAs in three years” and discuss 2026 catalysts across its modifier gene therapy platform for blindness diseases. The
✨ Onyx Summary Keros Therapeutics, Inc. announced the final results of its cash tender offer, repurchasing 10.95 million shares at $17.75 per share for approximately $194.4 million, representing about 35.9% of outstanding shares. The oversubscribed tender, which applied a final proration factor of roughly 62.3%, concludes
✨ Onyx Summary Perspective Therapeutics announced that members of its senior leadership team will participate in fireside chats and investor meetings at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and the Evercore 8th Annual Healthcare Conference on December 3, 2025. SEATTLE, Nov. 20, 2025 – November 20, 2025
✨ Onyx Summary Avidity Biosciences launched an FDA-authorized Managed Access Program in the United States to provide investigational delpacibart zotadirsen to eligible patients with Duchenne muscular dystrophy amenable to exon 44 skipping, addressing a population with no approved exon-skipping therapies. The program aligns with Avidity’s planned 2026 BLA submission for
✨ Onyx Summary Keros Therapeutics, Inc. announced preliminary results of its cash tender offer, expecting to repurchase 10.95 million shares at $17.75 per share for approximately $194.4 million, representing about 35.9% of outstanding shares. The oversubscribed tender concludes Keros’ previously announced $375 million capital return program, materially
✨ Onyx Summary Alzheon, Inc. announced it will present new long-term efficacy, safety, and quantitative systems pharmacology data for its oral Alzheimer’s therapy valiltramiprosate (ALZ-801) at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference in December 2025. The presentations will highlight three-year Phase 2 extension results and modeling
Jefferies Global Healthcare Conference in London Date: November 17-20, 2025 To view the webcast, please click here.
✨ Onyx Summary A new Harris Poll survey commissioned by ImmunityBio finds that most U.S. patients with non-muscle invasive bladder cancer receive limited discussion of treatment options despite heavy reliance on healthcare providers for guidance, and many seek alternatives to chemotherapy, including immunotherapy. The results underscore a communication gap in
✨ Onyx Summary Legend Biotech opened a new 31,000-square-foot R&D facility in Philadelphia to support expansion of its next-generation cell therapy pipeline, adding approximately 55 research staff and strengthening its U.S. footprint. The site enhances the company’s innovation capabilities alongside existing New Jersey operations and aligns
✨ Onyx Summary enGene priced its underwritten public offering of 12.6 million common shares and 2.7 million pre-funded warrants, raising approximately $130 million in gross proceeds, with a 30-day overallotment option available to underwriters. The financing, conducted under the company’s effective shelf registration, is expected to close on
✨ Onyx Summary Guardant Health launched the 34-member Single Namespace Working Group to establish an open standard for exabyte-scale data interoperability, creating a unified framework that links globally distributed data into a single namespace. The consortium’s transition to OASIS positions the standard for broad adoption, aiming to streamline data access
✨ Onyx Summary Legend Biotech reported third-quarter results highlighted by continued revenue growth for CARVYKTI, strengthened by updated survival data, expanded commercial manufacturing in Europe, and progress across its global clinical programs. The company ended the quarter with approximately $1.0 billion in cash and reduced its net loss year over
✨ Onyx Summary enGene initiated an underwritten public offering of its common shares, with all shares offered by the company and an additional 15% overallotment option available to underwriters, subject to market conditions. The offering will be conducted under enGene’s effective shelf registration and supports ongoing advancement of its non-viral
✨ Onyx Summary Kyverna Therapeutics reported third-quarter progress across its neuroimmunology CAR T franchise, including positive interim Phase 2 data in generalized myasthenia gravis, advancement of its registrational trials in stiff person syndrome and gMG, and continued expansion into additional autoimmune indications, supported by upcoming milestones such as an early-2026 SPS
✨ Onyx Summary Neochromosome and GlobalBio introduced an integrated platform that combines ALTHEA antibody libraries with the neoSwitch yeast system to enable rapid, in-house biologics discovery with streamlined transitions from display to secretion. The collaboration reduces the cost and duration of antibody screening by eliminating traditional library construction steps and providing
✨ Onyx Summary enGene reported additional preliminary Phase 2 LEGEND data for detalimogene voraplasmid in high-risk BCG-unresponsive NMIBC, showing a 63% complete response rate at any time and improved 6-month CR rates under an amended protocol, alongside a favorable safety profile across 125 patients. The company has aligned its primary endpoint
